Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NeurogesX raises $25 million

NGSX announced that on Sunday, it raised $25 million through a private

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE